Tumor Treatment Field Therapy (TTFT) - Policy Article

Tumor Treatment Field Therapy devices (HCPCS E0766) are covered under the DME benefit when the beneficiary meets the reasonable and necessary criteria in the related LCD and when a prior face-to-face encounter and Written Order Prior to Delivery (WOPD) are documented. E0766 is an FDA Class III device paid as a single monthly fee (frequent and substantial service category) that requires specific modifiers (KF always; KX when LCD initial/continued criteria and documented re-evaluation/benefit/adherence are met) and strict documentation including WOPD, proof of delivery, clinical re-evaluation between day 60–91 for continued coverage, and usage/adherence data available in the medical record.

"Tumor Treatment Field Therapy devices billed with HCPCS E0766 are covered under the Durable Medical Equipment benefit when the beneficiary meets the reasonable and necessary (R&N) requirements set ..."